Many unapproved fixed-dose combo drugs still sold in India
Though India’s Central Drugs Standard Control Organization (CDSCO) has issued a comprehensive list of fixed-dose combination (FDC) drugs approved by the Drugs Control General of India (DCGI), which includes a total of 1,125 FDCs covering all therapeutic categories, millions of unapproved formulations continue to be sold across the counter in India, sometimes proving lethal, reports The Pharma Letter’s India correspondent.
Many FDC drugs that relate to antidepressants, painkillers, muscle relaxants or even antispasmodics have found their way into the market without the requisite DCGI approval, though they have been issued licences from state drug regulators.
Some FDCs like paracetamol + diclofenac + chlorzoxazone, and dicyclomine + paracetamol + mefenamic acid, as well as alprazolam + melatonin among others are under the DCGI scanner.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Generics
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze